Navigation Links
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
Date:10/25/2013

GREENWOOD VILLAGE, Colo., Oct. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it was contacted by the New York Stock Exchange in light of unusual market activity in the Company's common stock on Thursday, October 24, 2013. In accordance with the New York Stock Exchange's usual practice, the Company announced that its policy is not to comment on unusual market activity; however, the management did summarize significant milestones achieved over the past ten weeks including:

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

  • Positive results for Ampion in osteoarthritis of the knee clinical trial
  • $25 million financing
  • Positive summary data from Luoxis Diagnostics' study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform
  • Positive results from Independent Panel Review of the interim analysis of the Optina trial for diabetic macular edema

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
3. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
4. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
5. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
6. Levine Leichtman Acquires Champion Manufacturing
7. Pro Athletes Team Up to Champion Gout Awareness
8. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
9. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Ampio Pharmaceuticals Provides Clinical Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Scientists writing in a 2017 ... stop the progressive destruction of joint cartilage in osteoarthritis are “on the close ... upper limb orthopedic surgeon Alejandro Badia, MD , founder and chief medical ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... Periodontics located in Moorestown and Medford, NJ, now welcome patients from Cherry Hill, ... strives to save natural teeth whenever possible. When tooth removal is necessary, they ...
(Date:9/17/2019)... ... ... the 6th year in a row, Mental Health America (MHA) released its annual ... of Columbia based on several mental health and access measures. This year, Pennsylvania came out ... on the trends of the last 6 years and shows that many are still not ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... ... Warriors , with the goal of providing resources to assist researchers and encourage ... a progressive disease causing abnormal iron deposits in the brain. , BPAN ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... day on Pacifica's Lambert Campus, 249 Lambert Road, Carpinteria, CA. The day ... Clinical Psychology, Counseling Psychology, and Mythological Studies. Program Faculty will host program-specific ...
(Date:9/12/2019)... ... September 12, 2019 , ... Donaldson ... national scale in two recent and well-renowned listing publications, the Inc. 5000 and ... for the 2019 year. , Dr. Jeffrey Donaldson, CEO and owner of ...
(Date:9/11/2019)... ... ... A September 2 article on CBS News details a new ... to suffer heart attacks, strokes, kidney failure, and heart disease versus a control group ... specialists Dr. Feiz and Associates says the study adds further evidence to an overwhelming ...
(Date:9/11/2019)... N.J. (PRWEB) , ... September 11, 2019 , ... ... management, will exhibit at the 2019 AHIMA Health Data and Information Conference in ... to stop by booth #505 to learn more about GRM’s healthcare information ...
Breaking Medicine News(10 mins):